Xiao Wu

Xiao Wu

Auto-generated profile, based on publicly available information

Xiao Wu

Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2025 in International Journal of Stroke
Verified
Journal Article
Closed access
XWXiao Wu
Xiao Wu
JLJialu Li
Jialu Li
TFTao Fu
Tao Fu
HWHongyun Wang
Hongyun Wang
WZWenting Zhang
Wenting Zhang
XGXiuhai Guo
Xiuhai Guo
Background: Mobile stroke units (MSUs) improve outcomes in acute ischemic stroke (AIS), but their effectiveness is constrained by limited service radii. Integrating a rendezvous strategy with emergency medical services (EMS) may extend the operational reach of MSUs in rural areas. Aim: We evaluated whether a novel rendezvous approach between MSUs and EMS could enhance thrombolysis efficiency for rural AIS patients in a larger service area. Methods: We conducted a single-center, pragmatic, non-randomized, operationally allocated comparative study in Suzhou, Anhui, from 1 January to 31 December 2024. When a suspected stroke call originated from a remote location, a nearby conventional ambulance was dispatched. Subsequently, the MSU was dispatched via an EMS call, met the EMS at a predetermined midway point en route to the stroke center, and treated the patient when MSU was available. Inclusion criteria were: age ⩾ 18 years; onset location ⩾ 20 km from the MSU center; and onset-to-call time ⩽ 4 h. Patients with a final diagnosis of cerebral ischemia were analyzed based on transport method (MSU rendezvous vs EMS only). The primary outcome was the thrombolysis rate; secondary outcomes included time metrics, 90-day functional prognosis, and incidence of symptomatic intracranial hemorrhage (sICH). Propensity score matching (PSM) was used to balance baseline characteristics. Results: A total of 307 patients with AIS were included; the median age was 72 years (IQR, 63–79), and 192 (62.50%) were male. One hundred ninety-three patients were transferred through rendezvous transport, and 114 patients were transferred through EMS-only. The median distance from onset location to hospital in the rendezvous transport group was 39.00 km (24.23 miles) (IQR 30.00–47.00 km), with a maximum of 68.00 km (42.25 miles). Compared with EMS-only transfers, patients transferred through rendezvous transport had a nearly 3-fold increase in thrombolysis rates (68.90% vs 17.50%, p < 0.001), reduced dispatch-to-door time by 12.5 min, door-to-needle time by 46 min, and onset-to-needle time by 60 min (all p < 0.001). In addition, in terms of clinical outcomes, patients in the rendezvous group had lower median 90-day modified Rankin Scale scores (2.0 (1.0–3.0) vs 3.0 (1.5–5.0), p < 0.001). These findings remained consistent after PSM. Conclusion: Our study demonstrates that the novel MSU-EMS rendezvous approach significantly improves thrombolysis rates and functional outcomes, serving as a viable strategy to expand acute stroke care to remote populations. Data access statement: Data collected for the study may be made available from the corresponding author to others upon reasonable request.

27 August 2025 in Brain and Behavior
Verified
Journal Article
Open access
QLQiu Liu
Qiu Liu
XWXiao Wu
Xiao Wu
DHDashuai Huang
Dashuai Huang
YWYanqing Wang
Yanqing Wang
HWHaibo Wu
Haibo Wu
XZXinchen Zhu
Xinchen Zhu
Introduction: Previous studies have demonstrated the benefits of anticoagulant therapy in acute ischemic stroke (AIS) of large artery atherosclerosis (LAA) etiology, although no prior research has examined the impact of the timing of anticoagulation initiation in this population.Methods: A retrospective cohort study was conducted to assess the effect of early argatroban administration on clinical outcomes in AIS with LAA. Patients were stratified into an early administration group and a late administration group based on the time from stroke onset to argatroban initiation: ≤24 h and >24 h. The primary outcome was the proportion of favorable outcome, defined as modified Rankin Scale (mRS) score 0–2 at 90 days. Secondary outcomes included the proportion of patients achieving mRS 0–1 at 90 days, the mRS score at 90 days, and changes in National Institutes of Health Stroke Scale (NIHSS) score from baseline to 7 days or discharge. Safety outcomes comprised symptomatic intracranial hemorrhage (sICH), early neurological deterioration (END) during hospitalization, and organ hemorrhage within 90 days. Adjustments for potential confounders were performed using logistic regression.Results: From February 2022 to February 2024, 401 AIS patients treated with argatroban were enrolled. After excluding patients with non‐LAA etiologies, thrombolysis, and follow‐up loss, 55 patients received argatroban ≤24 h after stroke onset, and 98 received it >24 h. At 90 days, 43.6% of the early administration group achieved favorable outcomes versus 27.6% of the later administration group (p = 0.024). One sICH occurred in the later administration group. END was observed in one (1.8%) patient in the early administration group and five (5.1%) in the later administration group.Conclusion: This is the first study to demonstrate that timely argatroban initiation may improve clinical outcomes in thrombolysis‐naive patients with LAA AIS. However, the results should be interpreted with caution due to the study's retrospective design and limited sample size.

22 July 2026 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
XJXueqiao Jiao
Xueqiao Jiao
RLRui Li
Rui Li
LLLulan Li
Lulan Li
XWXiao Wu
Xiao Wu
LWLu Wang
Lu Wang
XGXiuhai Guo
Xiuhai Guo
Aims: Chronic cerebral hypoperfusion drives the progression of intracranial atherosclerotic stenosis (ICAS) and increases ischemic risk. Endothelial angiogenic adaptation initially preserves cerebral perfusion but deteriorates with disease progression. We investigated whether the HCG11/QKI5 axis represents a regulatory node with therapeutic potential in cerebral hypoperfusion. Methods: Circulating hypoxia‐ and angiogenesis‐related biomarkers were compared between asymptomatic and symptomatic ICAS patients to reflect different progression stages. Endothelial function was assessed in oxygen–glucose deprivation models following HCG11 overexpression or QKI5 knockdown. A rat model of chronic cerebral hypoperfusion was used to evaluate temporal changes in vivo. Results: Pro‐angiogenic factors were elevated in asymptomatic ICAS but reduced in symptomatic patients, indicating progressive impairment of vascular compensation. HCG11 overexpression enhanced endothelial proliferation and tube formation, whereas QKI5 silencing attenuated these responses. These effects were associated with modulation of HIF‐1α/VEGF signaling. In vivo, early hypoperfusion activated QKI5 and angiogenic pathways, followed by a gradual decline during sustained hypoperfusion. Conclusion: Progressive attenuation of the HCG11/QKI5‐mediated angiogenic program may underlie endothelial adaptive failure in cerebral hypoperfusion. Targeting this RNA‐regulatory axis may represent a potential therapeutic strategy to preserve vascular compensation and mitigate disease progression in ICAS.

17 April 2026 in International Journal of Stroke
Verified
Journal Article
Closed access
FYFuxia Yang
Fuxia Yang
LWLu Wang
Lu Wang
XWXiao Wu
Xiao Wu
LLLulan Li
Lulan Li
XJXueqiao Jiao
Xueqiao Jiao
XGXiuhai Guo
Xiuhai Guo
Background: Covert brain infarction is a common neuroimaging-defined manifestation of covert cerebrovascular disease and is associated with increased risks of future stroke and cognitive decline. Covert brain infarction has been included as an outcome in randomized trials evaluating coagulation-pathway-targeting strategies. However, whether these strategies consistently reduce incident covert brain infarction and whether treatment effects on covert brain infarction parallel those for acute ischemic stroke remain uncertain. Methods: Following PRISMA 2020 guidelines, we searched PubMed, Ovid MEDLINE, Embase, and Web of Science through 10 November 2025, for randomized controlled trials and magnetic resonance imaging substudies enrolling patients without an established indication for anticoagulation. Eligible trials compared antithrombotic strategies targeting the coagulation pathway (oral anticoagulation or direct factor inhibition, with or without background antiplatelet therapy) with antiplatelet-based regimens and reported incident covert brain infarction on follow-up magnetic resonance imaging. Trial-level treatment effects for covert brain infarction, acute ischemic stroke, and their composite were compared. Exploratory cross-outcome comparisons were performed using the ratio of relative risks with prespecified interpretability bounds. Results: Six randomized trials met the inclusion criteria, encompassing diverse clinical populations and varying antiplatelet regimens in the control arms. In stratified analyses according to treatment structure, coagulation-pathway strategies were not associated with a statistically significant reduction in incident covert brain infarction compared with antiplatelet therapy alone, with similar estimates across treatment strata and no evidence of interaction (P_interaction = 0.249). An exploratory pooled estimate was similar (risk ratio, 0.95; 95% confidence interval, 0.81–1.12). Findings were consistent across covert brain infarction subtypes, including lacunar and non-lacunar lesions. In trials reporting all three outcomes, these strategies were not associated with significant reductions in covert brain infarction, acute ischemic stroke (risk ratio, 0.85; 95% confidence interval, 0.65–1.11), or their composite endpoint (risk ratio, 0.97; 95% confidence interval, 0.84–1.11). The composite endpoint was predominantly driven by covert brain infarction (~70% of events). Exploratory cross-outcome comparisons yielded point estimates favoring acute ischemic stroke over covert brain infarction, although confidence intervals crossed unity. Conclusion: In clinical settings without a mandatory indication for anticoagulation, coagulation-pathway strategies were not associated with reduced incident covert brain infarction compared with antiplatelet therapy. Although effect estimates for covert brain infarction and acute ischemic stroke were broadly similar, uncertainty remains. Composite endpoints predominantly driven by covert brain infarction warrant cautious interpretation when inferring treatment effects on clinically manifest ischemic stroke.